ABBOTT LABORATORIES (ABT)

As of 31 August 2026, short interest in ABT is 22,129,750 shares, down 494,434 shares over the last month. Over the last 48 readings it ranged from 11,828,281 shares (30 September 2024) to 24,846,147 shares (15 July 2026). At the reported average volume of 8.3M shares a day that is 2.7 days to cover.

<iframe src="https://xoomar.com/embed/stocks/abt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 11 September 2026, the short share of ABT volume is 31.4%, down 17.4 points over the last five sessions. Over the last 52 readings it ranged from 24.8% (16 July 2026) to 65.5% (4 September 2026). The latest reading is 17.1 points below the 30-session average of 48.5%, on 3.6M shares reported.

As of 13 August 2026, the fails-to-deliver balance in ABT is 106 shares, down 3,094 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (23 April 2026) to 1,714,305 shares (22 June 2026). The latest reading sits at the bottom of that range.

Insiders at ABT reported 4 open-market sells worth $46.9M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: MCCOY JOHN A. JR. (VICE PRESIDENT AND CONTROLLER) on 2026-09-02.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

3 Form 144 notices on file for ABT worth $46.8M at the prices reported; 3 in the last 90 days worth $46.8M. Latest: John A. McCoy, Jr. filed on 2026-09-02 to sell 27 shares ($3K) from 2026-09-02.

2 holders above 5% have filed on ABT, all on Schedule 13G (passive). The largest reported stake is Vanguard Capital Management at 7.5% of the class (130,676,776 shares), filed 2026-04-29 for an event on 2026-03-31.

10 of the 30 tracked managers held ABT at their latest 13F, $3.06B in total at quarter-end prices. Citadel Advisors is the largest at $1.09B (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q1 2026 (quarter ended 2026-03-31) ABBOTT LABORATORIES reported revenue of $11.16B, up 7.8% from the same quarter a year earlier, and net income of $1.08B (0.61 diluted EPS). In FY 2025 it generated $9.57B of operating cash flow and spent $893.0M on buybacks and $4.12B on dividends. As of 2026-03-31, cash was $6.80B against $29.64B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-03-31; shares outstanding as of 2026-03-31 from the cover page.

24 contract actions on file for ABT: $21.0M obligated in the last 90 days and $21.0M in the last 12 months across 2 awarding agencies. The largest was $2.4M from the Department of Veterans Affairs on 2026-07-01 (purchase of cost per reportable result laboratory supplies). Only actions large enough to reach the daily top list are counted, and agencies report with a lag.